Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme
Read the original here:
Novo Nordisk A/S – Share repurchase programme
Category Archives: Global News Feed
Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science
Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases
View original post here:
Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science
Prevail Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the following virtual investor conferences in October:
View original post here:
Prevail Therapeutics to Present at Upcoming Investor Conferences
Kane Biotech Appoints New Advisor
WINNIPEG, Manitoba, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Company,” “Kane Biotech”) today announced that it has entered into an agreement with Harbor Access LLC (“Harbor Access”), an investor relations advisory firm with offices in Canada and the United States.
Read more here:
Kane Biotech Appoints New Advisor
LIDDS Announces Data on Liproca Depot from Open Label Extension Study
UPPSALA, SWEDEN – LIDDS AB (publ) announced today results from the voluntary open-label extension (OLE) of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50 % of the patients remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. PSA levels in the remaining six patients were in average reduced by 28 % at 2 months post treatment and reduced PSA levels remained in 2 patients at the end of the study with PSA reductions of 43 % and 73 %.
Read the original post:
LIDDS Announces Data on Liproca Depot from Open Label Extension Study
Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy
MONTREAL, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced the appointment of Michael Pine as Senior Vice President of Business Development and Strategy, effective September 21, 2020. Mr. Pine’s responsibilities include developing Medexus’ product portfolio in both the U.S. and Canada.
The rest is here:
Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy
Unique Enhanced CBD Company – CANNASSIST INTL CORP. Commences Trading on the OTCQB under the Symbol: (CNSC)
FALLBROOK, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- CannAssist International Corporation (OTCQB: CNSC) (“Cannassist” or the “Company”) is pleased to announce the Company is now a new Publicly Traded Company on the OTC Markets Platform - OTCQB Markets Tier. The OTCQB requires a company to be fully reporting under SEC rules and guidelines as a means of accomplishing full transparency for Investors.
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters
WARREN, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for management of seizure clusters. The FDA issues a CRL to indicate that the review cycle for an application is complete but the application cannot be approved in its current form.
Catalyst Biosciences to Present at the Stifel Immunology and Inflammation Summit
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational research, will present at the Stifel Immunology and Inflammation Virtual Summit. Dr. Blouse will speak on a panel entitled: “The evolution of complement targeted therapies,” taking place on Thursday, October 1, 2020, at 9:00 AM Eastern Time.
The rest is here:
Catalyst Biosciences to Present at the Stifel Immunology and Inflammation Summit